The story of Sildenafil presents a complex picture for shareholders. While the initial introduction generated significant returns, the expiration of its exclusive rights opened the door to off-brand competitors, https://guideyoursocial.com/story6717005/sildenafil-and-big-pharma-a-risky-investment